Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression
Yu You, Diguang Wen, Lu Zeng, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 13, pp. 5001-5018
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

N6-methyladenosine-mediated gene regulation and therapeutic implications
Yujiao Liu, Dan Yang, Tao Liu, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 6, pp. 454-467
Closed Access | Times Cited: 60
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion
Xiaoxue Cao, Qishun Geng, Danping Fan, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 56
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Yan Li, Haoer Jin, Qingling Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 30
The emerging importance role of m6A modification in liver disease
Sheng Wang, Songsen Gao, Wufei Ye, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114669-114669
Open Access | Times Cited: 30
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma
Houhong Wang, Amao Tang, Yayun Cui, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Novel insight into RNA modifications in tumor immunity: Promising targets to prevent tumor immune escape
Yuxin Kong, Jie Yu, Shengfang Ge, et al.
The Innovation (2023) Vol. 4, Iss. 4, pp. 100452-100452
Open Access | Times Cited: 25
RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives
Shuibin Lin, Ming Kuang
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 4, pp. 267-281
Closed Access | Times Cited: 10
ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma
Hehua Ma, Yuxin Hong, Zhenzhen Xu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
RNA modifications in cancer
Han Wu, Shi Chen, Xiang Li, et al.
MedComm (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p
Shenqi Han, Lin Xue, Yi Wei, et al.
Advanced Science (2023) Vol. 10, Iss. 17
Open Access | Times Cited: 19
Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches
Reena Gupta, Mustafa M. Kadhim, Abduladheem Turki Jalil, et al.
Environmental Research (2023) Vol. 228, pp. 115767-115767
Closed Access | Times Cited: 17
RNA m6A methylation regulators in liver cancer
Qiaoping Xu, Ning Ren, Lanqi Ren, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2
Diguang Wen, Hang Xiao, Yueyi Gao, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Jun-Xiao Shi, Zhichao Zhang, Hao-zan Yin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Role of m6A modifications in immune evasion and immunotherapy
Chunyu Wu, Lvyuan Li, Qiling Tang, et al.
Medical Oncology (2024) Vol. 41, Iss. 6
Closed Access | Times Cited: 6
ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages
Xin Hua, Qiuli Xu, Ranpu Wu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy
Luo Ping, Shiqi Li, Xinghua Long
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188873-188873
Closed Access | Times Cited: 16
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
m6A demethylase ALKBH5 maintains stemness of intrahepatic cholangiocarcinoma by sustaining BUB1B expression and cell proliferation
Yuan Gao, Miao Yu, Zengyuan Liu, et al.
Translational Oncology (2024) Vol. 41, pp. 101858-101858
Open Access | Times Cited: 5
Demethylases in tumors and the tumor microenvironment: Key modifiers of N6-methyladenosine methylation
Junchen Guo, Liang Zhao, Meiqi Duan, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116479-116479
Open Access | Times Cited: 5
RNA modifications in the progression of liver diseases: from fatty liver to cancer
Simiao Li‐Sauerwine, Wajahat Z. Mehal, Xinshou Ouyang
Science China Life Sciences (2024) Vol. 67, Iss. 10, pp. 2105-2119
Open Access | Times Cited: 5
The role of m6A-mediated PD-1/PD-L1 in antitumor immunity
Li Liu, Long Liang, Hui Li, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115460-115460
Closed Access | Times Cited: 12
New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma
Yujia Li, Yangling Qiu, Meng-ran Li, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1130-1141
Closed Access | Times Cited: 4
Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy
Ying Wang, Longxiang Su, Zhansheng Hu, et al.
APOPTOSIS (2024) Vol. 29, Iss. 9-10, pp. 1429-1453
Closed Access | Times Cited: 4
M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms
Miaochun Fang, Liwen Ye, Yue Zhu, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 157-157
Open Access
Page 1 - Next Page

Scroll to top